Evaluating blood pressure management in patients with B-cell cancers on specific treatments
Official title: Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study
Run by Mayo Clinic · NCT06151730 · Data updated 2026-11-12
This study is trying to see how blood pressure changes in people with B-cell cancers who are being treated with a specific type of medication, and what the best ways are to manage any high blood pressure they might develop.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | January 5, 2024 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT06151730 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, or marginal zone lymphoma who are starting treatment with BTKis.
✕Probably not a fit
Patients with known central nervous system involvement of their B-cell malignancy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the incidence of new and worsening hypertension in patients with B-cell malignancies undergoing treatment with Bruton Tyrosine Kinase Inhibitors (BTKis). It will identify hemodynamic changes associated with hypertension using impedance cardiography and determine optimal antihypertensive strategies. Additionally, the study will compare major adverse cardiovascular event (MACE) rates between patients experiencing hypertension and those who do not while on BTKis. Participants will attend hypertension clinic visits and undergo various monitoring and testing procedures throughout the study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of hypertension in patients with B-cell malignancies, potentially reducing cardiovascular risks.
How similar studies have gone: While this approach is novel in the context of BTKis and hypertension management, similar studies have shown the importance of monitoring cardiovascular health in cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up Exclusion Criteria: * Patients with known central nervous system (CNS) involvement of their B-cell malignancy
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Joerg Herrmann, MD — Mayo Clinic in Rochester
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral AS-1763 treatment for patients with certain blood cancers
This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.
-
Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL
This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.
-
Personalized exercise and nutrition program to reduce cancer-related fatigue
This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).
-
Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310
This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.
-
Gene therapy for certain blood cancers
This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.
-
Using CAR T cells to treat certain types of B cell lymphomas
This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.